TL;DR
A MedPage Today endocrinology roundup published October 20, 2026, summarized research and industry developments, including a study finding that about one-quarter of active-duty U.S. Army men had a single morning testosterone reading below 300 ng/dL. It also reported CDC figures on menopause symptoms and prescription treatment, and a Reddit analysis of adverse-event terms posted by people who said they used unapproved retatrutide. The findings have important limits: a single testosterone result does not establish a diagnosis, and Reddit reports cannot determine how often a drug causes a side effect.
A MedPage Today endocrinology roundup published October 20, 2026, highlighted research finding that roughly one-quarter of active-duty U.S. Army men had a single morning testosterone reading below 300 ng/dL, alongside new figures on menopause symptoms and an analysis of Reddit posts about retatrutide. The three items concern different populations and evidence types; none, on its own, establishes a diagnosis or proves that a reported symptom was caused by a drug.
The Army finding, attributed in the roundup to research in JAMA, used 300 ng/dL as a commonly used cutoff for low testosterone. The reported result was based on one morning concentration per person. The roundup does not provide the study’s sample size, exact percentage, participant health details or follow-up results, so the figure should not be read as the share of soldiers diagnosed with testosterone deficiency.
A CDC report cited by MedPage Today found that nearly half of U.S. women ages 40 to 60 reported menopausal symptoms in 2025. Among that group, 15.6% said they were taking prescription medication for those symptoms. The summary does not specify which symptoms or medicines were included, or whether medication use reflected symptom severity, access or treatment preference.
The roundup also described a JAMA Network Open analysis of Reddit users who reported taking retatrutide, an unapproved weight-loss drug. Commonly mentioned adverse-event terms included appetite increases, fatigue, increased energy, insomnia, increased heart rate and muscle-related symptoms. These are terms users posted, not medically verified events or proof of causation. The roundup also cited Novo Nordisk’s statement that post-hoc analyses of a phase III trial found average weight loss of 25% among women taking investigational semaglutide plus cagrilintide, with similar results across pre-, peri- and postmenopausal stages.
Three Findings, Three Evidence Limits
The reports draw attention to issues that can affect military health, midlife women’s care and the safety monitoring of weight-loss drugs. The Army result may prompt questions about how testosterone is measured and when a low reading leads to clinical evaluation. But a population-level finding from a single measurement cannot show how many soldiers have persistent low levels or related symptoms.
The CDC figures indicate that menopausal symptoms were commonly reported among women aged 40 to 60, while a smaller share reported prescription treatment. Those numbers can inform discussions about treatment access and use, but they do not explain why people did or did not take medication. The Reddit analysis offers a snapshot of concerns people share online about retatrutide, yet it cannot estimate risk: users are not a representative sample, and posts do not confirm exposure or clinical diagnoses.
How the Findings Were Reported
The three central items appeared in a short endocrinology news roundup, rather than a single study comparing the topics. MedPage Today attributed the Army testosterone finding to JAMA, the menopause statistics to a CDC report, and the retatrutide post analysis to JAMA Network Open. Each source addresses a different question and uses a different kind of evidence.
The roundup included other developments as well: a National Health Interview Survey finding that one in six adults with type 1 diabetes reported moderate to severe depression or anxiety symptoms; a meta-analysis linking greater weight loss from GLP-1 drugs and emerging multi-hormone treatments with larger blood-pressure drops; and early research on possible anti-aging effects of GLP-1 drugs. It also reported that Walmart planned to cover more than 250 prescription drugs, including some insulins and diabetes GLP-1 drugs, at no cost for employees in 2027. These are separate findings and announcements, not evidence that one treatment applies to every group discussed.
“Roughly a quarter of active-duty U.S. Army men had a single morning testosterone concentration under 300 ng/dL.”
— MedPage Today, describing the Army finding
What These Numbers Cannot Establish
The source summary does not provide enough detail to assess the Army study’s design, the exact share below the cutoff, or whether participants had repeat testing or symptoms. A single testosterone measurement should not be treated as evidence that every person below the threshold has a clinical disorder. The CDC summary likewise leaves out the survey methods and the types of treatment counted.
For retatrutide, the Reddit analysis cannot show how frequently side effects occur among all users, whether the people posting took a verified product, or whether other factors explained their symptoms. Retatrutide is described in the source as unapproved; the roundup gives no regulatory update or full safety results from clinical trials. The semaglutide-cagrilintide weight-loss figure is also identified as a company statement based on post-hoc analyses, and the summary does not provide the trial’s full methods or results.
Further Study and Safety Data
Readers seeking firmer conclusions will need the full studies and reports, including methods, sample sizes, participant characteristics and clinical outcomes. For the Army finding, repeat measurements and information about symptoms would help clarify how a low reading relates to diagnosed testosterone deficiency. For menopause care, fuller CDC data could explain treatment patterns and the range of medications involved.
Retatrutide’s safety profile cannot be established from social-media posts; clinical-trial evidence and any relevant regulatory decisions will be needed to assess its risks. The roundup does not announce a new study date or a specific next milestone for the drug. It reports Walmart’s employee drug-coverage plan for 2027 and company-reported trial analyses, but does not provide further implementation details or a regulatory timetable for the semaglutide-cagrilintide combination.
Key Questions
Does the Army finding mean one-quarter of male soldiers have diagnosed low testosterone?
No. The roundup reports that roughly one-quarter had a single morning reading below 300 ng/dL, a commonly used cutoff. It does not say that all those men received a clinical diagnosis.
What did the CDC report say about menopause?
Nearly half of U.S. women ages 40 to 60 reported menopausal symptoms in 2025. The CDC figures summarized by MedPage Today say 15.6% of that age group were taking prescription medication for those symptoms.
Do Reddit posts prove retatrutide causes the listed symptoms?
No. The analysis identified adverse-event terms in posts by people reporting retatrutide use. Online reports cannot confirm the drug caused a symptom or establish how common it is among users.
Is retatrutide approved for weight loss?
The source describes retatrutide as an unapproved weight-loss drug. The roundup does not provide a later regulatory decision or a timetable for approval.
Source: rss
